IQV IQVIA Holdings Inc

Cwm LLC significantly increased its stake in IQVIA Holdings Inc. by 37.8% in Q3, purchasing an additional 12,363 shares and bringing its total holdings to 45,068 shares valued at approximately $8.56 million. IQVIA exceeded Q3 expectations with $3.00 EPS on revenues of $4.10 billion, and analysts widely rate the stock as a "Moderate Buy" with an average target price of $243.19. Institutional investors hold a substantial 89.62% of IQVIA, while insiders, despite a recent sale by Eric Sherbet, retain 1.60% ownership.

IQVIA Holdings, Inc. (IQV) exhibits strong potential for retention in portfolios due to its collaboration with Amazon Web Services enhancing its AI capabilities in life sciences, a robust R&DS backlog, and a commitment to shareholder returns through share repurchases. Despite these strengths, the company faces significant challenges with its liquidity, as indicated by a consistently falling current ratio. IQVIA currently holds a Zacks Rank of #3 (Hold), with other stocks like Byrna Technologies (BYRN) and Veralto Corporation (VLTO) receiving higher ranks.

IQVIA (IQV) stock has outperformed its industry significantly, driven by an expected long-term EPS growth rate of 8.38% and strong collaborations with Amazon Web Services ("AWS") for AI integration in life sciences. The company shows robust revenue visibility with a growing R&DS backlog and active share repurchase programs. However, challenges include a consistently falling current ratio, indicating liquidity concerns.

Marathon Asset Management Ltd has reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 24.1%, selling 40,797 shares to hold 128,464 shares valued at $24.4 million. Despite this sale, institutional ownership remains high at 89.62%, and analysts maintain a "Moderate Buy" rating with a consensus price target of $243.19. IQVIA also reported strong Q3 earnings, exceeding estimates and providing positive FY2025 guidance.

Pacer Advisors Inc. significantly reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 29.1% during the third quarter, selling 299,354 shares and now owning 728,498 shares valued at $138.37 million. This move comes as other institutional investors have either boosted or initiated positions in the medical research company. IQVIA recently reported strong third-quarter earnings, beating analyst estimates, and currently holds a "Moderate Buy" rating from analysts with an average target price of $243.19.

IQVIA Holdings Inc. (NYSE:IQV) is analyzed for its debt levels relative to its balance sheet health. The company has a significant debt of US$15.0 billion, which reduces to US$13.0 billion net debt after accounting for cash reserves. While its debt-to-EBITDA ratio is 4.5 and EBIT covers interest expense 3.4 times, suggesting manageability, its total liabilities significantly exceed its cash and near-term receivables, leading to a cautious outlook on its debt levels despite its strong free cash flow generation.